

91460\_Auto\_Edited.docx

**Name of Journal:** *World Journal of Clinical Oncology*

**Manuscript NO:** 91460

**Manuscript Type:** ORIGINAL ARTICLE

*Retrospective Cohort Study*

**Comparative effectiveness of immunotherapy and chemotherapy in patients with metastatic colorectal cancer stratified by microsatellite instability status**

Immunotherapy in colorectal cancer

Chengu Niu, Jing Zhang, Aniket-Vijav Rao, Utsav Joshi, patrick okolo

## **Abstract**

### **BACKGROUND**

Immunotherapy have demonstrated promising outcomes in patients with microsatellite instability-high (MSI-H) metastatic colorectal cancer. However, the comparative effectiveness of Immunotherapy and chemotherapy for patients with microsatellite instability-low (MSI-L), and microsatellite stable (MSS) metastatic colorectal cancer remains unclear.

### **AIM**

To investigate immunotherapy *vs* chemotherapy for treatment of MSI-L/MSS metastatic colorectal cancer, and to evaluate the success of immunotherapy against chemotherapy in managing MSI-H metastatic colorectal cancer during a follow-up of 50 months.

### **METHODS**

We conducted a retrospective cohort study using the National Cancer Database (NCDB) to evaluate the overall survival (OS) of patients with metastatic colorectal cancer treated with immunotherapy or chemotherapy. The study population was stratified by MSI status (MSI-H, MSI-L, and MSS). Multivariable Cox proportional hazard models were used to assess the association between treatment modality and OS, adjusting for potential confounders.

### **RESULTS**

A total of 21,951 patients with metastatic colorectal cancer were included in the analysis, of which 2,358 were MSI-H, and 19,593 were MSI-L/MSS. In the MSI-H cohort, immunotherapy treatment ( $n = 142$ ) was associated with a significantly improved median OS compared to chemotherapy ( $n = 860$ ). After adjusting for potential confounders, immunotherapy treatment remained significantly associated with better OS in the MSI-H cohort (adjusted hazard ratio [aHR] 0.57, 95%CI: 0.43-0.77,  $p < 0.001$ ).

In the MSS cohort, no significant difference in median OS was observed between immunotherapy treatment and chemotherapy (aHR 0.94, 95%CI: 0.69-1.29,  $P = 0.715$ ).

## CONCLUSION

In this population-based study using the NCDB, immunotherapy treatment was associated with significantly improved OS compared to chemotherapy in patients with MSI-H metastatic colorectal cancer, but not in those with MSI-L/MSS metastatic colorectal cancer. Further studies are warranted to determine the optimal therapeutic approach for patients with MSI-L/MSS metastatic colorectal cancer

**Key Words:** Immunotherapy; Chemotherapy; Metastatic Colorectal cancer; Microsatellite instability.

Niu C, Zhang J, Rao AV, Joshi U, okolo P. Comparative effectiveness of immunotherapy and chemotherapy in patients with metastatic colorectal cancer stratified by microsatellite instability status. *World J Clin Oncol* 2024; In press

**Core Tip:** Our population-based study demonstrates that immunotherapy treatment is associated with significantly improved overall survival in patients with microsatellite instability-high metastatic colorectal cancer. However, immunotherapy does not significantly benefit patients with microsatellite stable metastatic colorectal cancer. The lower response rates to immunotherapy in microsatellite stable tumors can be attributed to the lower tumor mutational burden and reduced immunogenicity compared to microsatellite instability-high tumors. These findings indicate that while immunotherapy is a promising treatment for microsatellite instability-high colorectal cancer, its efficacy in microsatellite stable cases remains uncertain, warranting further investigation to develop targeted therapies for these patients.

2

## INTRODUCTION

Colorectal cancer is globally recognized as the third most widespread form of cancer and the second leading cause of death due to cancer<sup>[1,2]</sup>. The 2023 statistics from the American Cancer Society predict that there will be 153,020 new cases of colorectal cancer in the United States, with an estimated death count of 52,550<sup>[3]</sup>. The treatment of metastatic colorectal cancer poses a significant difficulty in clinical practice, with an overall 5-year survival rate of just 14%<sup>[4]</sup>. Conventional frontline therapies for this condition often consist of Fluoropyrimidine-based chemotherapy, complemented by targeted treatments including anti-vascular endothelial growth factor and anti-epidermal growth factor receptor agents<sup>[5-8]</sup>. A mounting body of evidence suggests that tumors with high microsatellite instability (MSI-H) may not be ideally suited to standard chemotherapy treatments<sup>[9-11]</sup>. MSI-H colorectal cancers, known for their high mutation rate, generate neoantigens that activate the immune system<sup>[11]</sup>. The KEYNOTE-177 and CheckMate-142 trials have demonstrated that immunotherapy offers significant clinical benefit in the treatment of MSI-H/dMMR metastatic colorectal cancer<sup>[12,13]</sup>. While immunotherapy has shown enhanced effectiveness in treating metastatic colorectal cancers characterized by MSI-H, it demonstrates limited success in microsatellite stable (MSS) variants, which account for the majority (95%) of these cases<sup>[14]</sup>.

A thorough literature review highlights a significant data gap in immunotherapy application for MSS patients. Consequently, the majority of those with MSS metastatic colorectal cancer have yet to see the benefits of current immunotherapy methods<sup>[14]</sup>. Meanwhile, large-scale data evaluating the relationship between MSI-H metastatic colorectal cancer and immunotherapy is scarce. Hence, leveraging the National Cancer Data Base (NCDB)—which captures over 70% of new cancer diagnoses in the U.S.<sup>[15]</sup>—this research intends to (1) investigate immunotherapy *vs* chemotherapy for treatment of MSS colorectal cancer, and (2) evaluate the success of immunotherapy against chemotherapy in managing MSI-H metastatic colorectal cancer during a follow-up of 50 months.

## **MATERIALS AND METHODS**

### *Data source and study population*

Our research involved a retrospective cohort analysis utilizing the NCDB, a collaborative initiative between the American College of Surgeons and the American Cancer Society, encompassing over 70% of new cancer diagnoses in the United States. [16] Our research entailed a detailed retrospective analysis utilizing the NCDB, focusing on a cohort of adult patients diagnosed with stage IV colorectal adenocarcinoma on 2020. This study encompassed patients identified by primary tumor site codes C18 (malignant neoplasm of the colon) and C20 (malignant neoplasm of the rectum), which are ICD-10 codes. The analysis concentrated on key variables, including gender, age at diagnosis, and tumor size. Tumor size was categorized into two clinically relevant groups:  $\leq 20\text{mm}$  and  $>20\text{mm}$ . Furthermore, patient microsatellite instability (MSI) status was a crucial variable, alongside the initial treatment strategy, categorized into immunotherapy and chemotherapy. Vital status was utilized to determine whether each patient in the study was deceased or alive. The present study was a database analysis using de-identified data; therefore, institutional review board approval was not required for this type of study.

### *Study population characteristics*

In profiling the study population, we gathered demographic information and clinical characteristics. This included age at diagnosis, gender, race, socioeconomic background, and types of healthcare facilities where treatment was administered. The Charlson-Deyo Comorbidity score was employed to evaluate comorbid conditions, with scores truncated to 0, 1, 2, or 3 (for scores  $\geq 3$ ). Data regarding treatment modalities, immunotherapy, chemotherapy, and additional supportive treatments, were analyzed with a primary focus on the initial course of therapy.

### *Outcome of interest*

The focus of our research was on the initial systemic therapy administered to patients, divided into two categories: immunotherapy and chemotherapy, including both single-agent and combination therapies. The primary outcome for evaluation was overall survival, which we defined as the period from the diagnosis of metastatic colorectal cancer until death from any cause or the most recent follow-up. We tracked overall survival from the point of cancer diagnosis, monitoring up to the occurrence of death or the last recorded follow-up, and calculated both one-year, three-year, and 50 months survival rates. Our methodology and data analysis conformed to the Strengthening the Reporting of Observational Studies in Epidemiology guidelines.

### *Statistical analysis*

All analyses were conducted using Stata version 17.0 (StataCorp, College Station, Texas 77845 USA). We calculated the median follow-up duration, with survival time measured from the date of diagnosis to either death or the last known contact. Descriptive statistics were employed to summarize the baseline characteristics of the patient cohort. The Kaplan-Meier method was used to estimate survival probabilities, and the log-rank test was applied to compare differences between prognostic factors. To assess the impact of various factors on five-year overall survival, Cox proportional hazards models were utilized. These models generated hazard ratios (HR) along with their 95% confidence intervals (CIs). Additionally, multivariate analysis was conducted to calculate the adjusted HR (aHR), accounting for variables like race, gender, and age. The proportional hazards assumptions of our models were graphically verified. Furthermore, the accuracy of the American Joint Committee on Cancer sixth edition staging system was evaluated by calculating a concordance index, complete with 95% CIs. All statistical tests were two-sided, with a significance threshold set at  $p < 0.05$ .

## **RESULTS**

### *Baseline characteristics of the study cohort*

Our comprehensive study analyzed 21,951 patients diagnosed with stage IV colorectal cancer, categorized based on MSI status. Within this cohort, 2,358 patients were identified as MSI-H, and 19,593 as MSS. The treatment breakdown revealed that in the MSI-H group, 142 patients opted for the novel approach of immunotherapy, while a significant portion, 860 patients, underwent conventional chemotherapy. Similarly, in the MSS group, 88 patients received immunotherapy, compared to 8,085 who chose chemotherapy. This distinction in treatment choices underscores the evolving landscape of cancer therapeutics. The average follow-up duration for patients receiving immunotherapy in the MSI-H group was  $21.91 \pm 12.23$  months, and  $19.83 \pm 12.89$  months for those receiving chemotherapy. The MSS group had a slightly longer mean follow-up of  $18.48 \pm 11.37$  months for immunotherapy and  $20.61 \pm 11.71$  months for chemotherapy. The median ages in these groups varied, with 77 years and 63 years for MSI-H patients on immunotherapy and chemotherapy, respectively, and 67.5 and 62 years for the MSS cohort, reflecting the demographic diversity of the study population (Table 1).

### *Survival Outcomes Based on MSI Status*

Analyzing the survival outcomes, MSI-H patients who received immunotherapy experienced a pronounced survival benefit with an aHR of 0.57 (95%CI: 0.43-0.77), suggesting a robust response to this treatment modality. This benefit contrasts with the MSS group, where immunotherapy did not provide a significant survival advantage (aHR = 0.94; 95%CI: 0.69-1.29). The one-year survival rates further illustrate this difference: 71.96% for MSS patients on immunotherapy and 76.78% for those on chemotherapy, compared to 76.55% and 69.91% for MSI-H patients, respectively. A



similar pattern was observed at the three-year follow-up, with survival rates of 48.06% for immunotherapy and 40.38% for chemotherapy in the MSS group, and 50.96% and 44.35% in the MSI-H group, indicating a more pronounced long-term benefit for immunotherapy in the MSI-H category (Table 2 and 3). The Kaplan-Meier survival curves for these groups are depicted in Figures 1 (MSS) and 2 (MSI-H).

#### *KRAS Mutation and Survival*

The study also delved into the impact of KRAS mutation status on treatment outcomes. For KRAS wild-type patients, <sup>1</sup> no significant difference in survival was observed between immunotherapy and chemotherapy (HR = 1.16; 95%CI: 0.86-1.56). However, in KRAS mutated patients, a trend toward improved survival was noted with immunotherapy (HR = 0.67; 95%CI: 0.42-1.07), hinting at the potential effectiveness of personalized treatment based on genetic profiles. This trend, though not statistically significant, signals a possible avenue for enhancing patient-specific treatment strategies in the future (Table 4). The corresponding survival curves are shown in Figures 3 (KRAS wild type) and 4 (KRAS mutated type).

### **DISCUSSION**

In our study, utilizing data from the NCDB, we observed that in patients with MSI-H metastatic colorectal cancer, immunotherapy significantly improved OS in long-term follow-up, aligning with some previous studies<sup>[12,13]</sup>. However, our results reveal no significant survival benefit with immunotherapy in MSI-L/MSS patients. These findings suggest that immunotherapy treatment should be considered for patients with MSI-H metastatic colorectal cancer, while further studies are warranted to determine the optimal therapeutic approach for patients with MSS metastatic colorectal cancer.

Our findings echo those of Le *et al* and Overman *et al*, underscoring the divergent responses to immunotherapy in MSI-H *vs* MSI-L/MSS metastatic colorectal

cancers<sup>[12,13]</sup>. Le *et al*'s research delves into the efficacy of PD-1 blockade in mismatch repair-deficient tumors, showing significant positive responses in colorectal and other cancers with high microsatellite instability – a notable advancement in immunotherapy for these patients<sup>[12]</sup>. Similarly, Overman *et al*'s study focuses on the use of Nivolumab, a PD-1 inhibitor, in treating metastatic colorectal cancer patients with mismatch repair deficiencies or high microsatellite instability, adding to the growing body of evidence in this field<sup>[13]</sup>. Boland and colleagues highlighted the significant influence of MSI on colorectal cancer, particularly emphasizing the unique tumor characteristics and varied treatment responses associated with it<sup>[17]</sup>. These findings collectively underline the intricacies of tumor biology and the critical need to incorporate MSI status in devising treatment strategies.

Our research indicates that immunotherapy does not significantly benefit patients with MSI-L/MSS metastatic colorectal cancer, a finding that contrasts sharply with the substantial efficacy observed in MSI-H metastatic colorectal cancer. This notable difference may imply a potential resistance to immunotherapeutic strategies within the MSI-L/MSS subtype, hinting at a complex, yet unexplored aspect of its molecular profile. The lower response rates to immunotherapy in MSI-L/MSS tumors can be attributed to the lower tumor mutational burden and reduced immunogenicity compared to MSI-H tumors<sup>[17]</sup>. Nonetheless, several ongoing clinical trials are investigating combination strategies, such as the use of immunotherapy with chemotherapy, targeted therapies, to enhance the efficacy of immunotherapy in MSI-L/MSS metastatic colorectal cancer<sup>[18-21]</sup>.

While at first glance these results in MSI-L/MSS metastatic colorectal cancer patients may seem like a setback, they actually represent a significant advancement in our understanding of metastatic colorectal cancer. They highlight the necessity of re-evaluating our current therapeutic approaches and underscore the importance of further investigation into the distinct molecular features of the MSI-L/MSS subtype. Our findings serve as a catalyst for this critical research, driving the development of

more targeted and effective treatment strategies for metastatic colorectal cancer. Echoing the sentiments of Mármol *et al*, our study supports the push towards personalized medicine in the treatment of metastatic colorectal cancer<sup>[22]</sup>. Tailoring treatments based on genetic markers such as MSI can potentially lead to more effective and targeted therapies.

In our study, the evaluation of OS benefits associated with immunotherapy, in comparison to chemotherapy, revealed no significant differences in both KRAS mutated and wild-type colorectal cancer populations. This outcome highlights the complex interplay between genetic profiles and tumor response to immunotherapeutic agents. Existing literature has consistently shown that KRAS mutations are a common feature in colorectal cancers, often correlating with a challenging prognosis and reduced responsiveness to certain treatments, such as anti-EGFR therapies. The lack of a distinct OS advantage in either KRAS cohort within our study may suggest a broader pattern of resistance or insensitivity to immunotherapy across these genetic variations. This observation emphasizes the critical need for developing more refined and individualized treatment strategies, especially for KRAS-mutated colorectal cancer, a substantial subset of the patient population.

Our study underscores the necessity of integrating genetic profiling into therapeutic decision-making, potentially improving patient outcomes in metastatic colorectal cancer. Such an approach aligns with the evolving paradigm of personalized medicine. However, this endeavor requires careful consideration of the metastatic colorectal cancer 's genetic heterogeneity, the development of sophisticated genomic analysis techniques, and a thorough understanding of the practicalities and challenges in implementing personalized treatment regimens, including economic and logistical factors.

#### *Limits of the study*

This study encountered several limitations that are important to acknowledge. Firstly, the retrospective nature of the study may have introduced selection bias, as the choice of treatment might have been influenced by unmeasured factors. Additionally, the NCDB lacks detailed information on treatment regimens, duration, and response to therapy, which precludes further exploration of the impact of different agents, combinations, or lines of therapy. Information on potential predictive biomarkers, such as tumor mutational burden and PD-L1 expression, was not available. Another significant limitation is the variability in data due to incomplete information on specific molecular characteristics of the colorectal tumors in some patients, which may impact the study's conclusions. Lastly, our study population included patients diagnosed till 2020, which may not reflect the most recent advances in metastatic colorectal cancer treatment. Given these limitations, it is crucial to undertake further research in this field to enhance our understanding of MSS metastatic colorectal cancer and to develop more effective treatment strategies.

## **CONCLUSION**

Our population-based study demonstrates that immunotherapy treatment is associated with significantly improved OS in patients with MSI-H metastatic colorectal cancer, but not in those with MSI-L/MSS metastatic colorectal cancer. These findings suggest that immunotherapy treatment should be considered for patients with MSI-H metastatic colorectal cancer, while further studies are warranted to determine the optimal therapeutic approach for patients with MSI-L/MSS metastatic colorectal cancer.

## **ARTICLE HIGHLIGHTS**

### ***Research background***

Colorectal cancer is the third most common cancer globally and poses significant challenges in its metastatic stage. Microsatellite instability (MSI) plays a key role in determining the effectiveness of treatments like chemotherapy and immunotherapy.

### *Research motivation*

This study is motivated by the need to understand the differential effectiveness of immunotherapy and chemotherapy in metastatic colorectal cancer, especially when stratified by MSI status, a factor not well explored in large-scale studies.

### *Research objectives*

The primary objective was to investigate the comparative effectiveness of immunotherapy and chemotherapy in treating metastatic colorectal cancer, specifically focusing on the stratification by MSI status using data from the National Cancer Data Base (NCDB).

### *Research methods*

A retrospective cohort analysis was conducted using NCDB data for adult patients diagnosed with stage IV colorectal adenocarcinoma in 2020. The study focused on assessing overall survival in relation to treatment type (immunotherapy vs. chemotherapy) and MSI status.

### *Research results*

The study analyzed 21,951 patients, finding significant benefits of immunotherapy in MSI-H metastatic colorectal cancer but not in MSI-L/MSS cases. It also explored the influence of KRAS mutation on treatment outcomes.

### *Research conclusions*

Immunotherapy was found to be significantly effective in patients with MSI-H metastatic colorectal cancer but showed limited efficacy in MSI-L/MSS patients. The study underscores the importance of considering MSI status in treatment planning.

### *Research perspectives*

The findings advocate for personalized treatment approaches in metastatic colorectal cancer, emphasizing the need for further research into tailored therapies based on MSI status and genetic profiling.

ORIGINALITY REPORT

2%

SIMILARITY INDEX

PRIMARY SOURCES

1	<a href="http://www.ncbi.nlm.nih.gov">www.ncbi.nlm.nih.gov</a> Internet	32 words — 1%
2	Shereen Ahmed Ahmed Qalawa. "Community knowledge toward risk prediction of colorectal cancer", Egyptian Journal of Health Care, 2021 Crossref	17 words — 1%
3	<a href="http://www.wjgnet.com">www.wjgnet.com</a> Internet	14 words — < 1%
4	<a href="http://wjso.biomedcentral.com">wjso.biomedcentral.com</a> Internet	12 words — < 1%